Meridian Bioscience Inc
VIVO
VIVO was delisted on the 30th of January, 2023.
1 hedge funds and large institutions have $34 invested in Meridian Bioscience Inc in 2023 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.
50% less funds holding
Funds holding: 2 → 1 (-1)
100% less capital invested
Capital invested by funds: $49K → $34 (-$49K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BTI
Blue Trust Inc
Alpharetta,
Georgia
|
-$49K |
VIVO Hedge Fund Activity: Q2 2023 in Review
1 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Meridian Bioscience Inc (VIVO) for Q2 2023, worth a combined $34 — down 100% from $49K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of VIVO and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Blue Trust Inc, exiting entirely with an estimated $49K sold.
- 1 institutional investor held Meridian Bioscience Inc (VIVO) as of Q2 2023, down from 2 in Q1 2023.
- Funds reported $34 of Meridian Bioscience Inc stock for Q2 2023, down 100% quarter-over-quarter.
- 0 funds opened new Meridian Bioscience Inc positions in Q2 2023 and 1 closed out, a net change of -1 holder.
- The largest Meridian Bioscience Inc seller in Q2 2023 was Blue Trust Inc, an estimated $49K sold.
Based on aggregated 13F filings for Q2 2023.